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Abstract 
 
Background: Genome-wide association studies (GWAS) have so far reported 12 loci associated with 
serous epithelial ovarian cancer (EOC) risk. We hypothesized that some of these loci function through 
nearby transcription factor (TF) genes and that putative target genes of these TFs as identified by co-
expression may also be enriched for additional EOC risk associations. 
Methods: We selected TF genes within 1 Mb of the top signal at the 12 genome-wide significant risk 
loci. Mutual information, a form of correlation, was used to build networks of genes strongly co-
expressed with each selected TF gene in the unified microarray data set of 489 serous EOC tumors from 
The Cancer Genome Atlas. Genes represented in this data set were subsequently ranked using a gene-
level test based on results for germline SNPs from a serous EOC GWAS meta-analysis (2,196 cases/4,396 
controls). 
Results: Gene set enrichment analysis identified six networks centered on TF genes (HOXB2, HOXB5, 
HOXB6, HOXB7 at 17q21.32 and HOXD1, HOXD3 at 2q31) that were significantly enriched for genes 
from the risk-associated end of the ranked list (P<0.05 and FDR<0.05). These results were replicated 
(P<0.05) using an independent association study (7,035 cases/21,693 controls). Genes underlying 
enrichment in the six networks were pooled into a combined network. 
Conclusion: We identified a HOX-centric network associated with serous EOC risk containing several 
genes with known or emerging roles in serous EOC development. 
Impact: Network analysis integrating large, context-specific data sets has the potential to offer 
mechanistic insights into cancer susceptibility and prioritize genes for experimental characterization. 
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Introduction 
 
The genetic architecture of inherited susceptibility to epithelial ovarian cancer (EOC) appears 
similar to other hormone-related cancers, but fewer EOC risk loci have been discovered compared to 
breast and prostate cancer, probably due to restricted sample size (1). Genome-wide association studies 
(GWAS) have so far identified 12 risk loci associated with serous EOC, the most common subtype of 
EOC (1–7). These account for 4 per cent of the excess familial risk of EOC, while rare, high-penetrance 
mutations in genes such as BRCA1 and BRCA2 explain about 40 per cent (8). This suggests that many 
undiscovered common serous EOC risk variants exist. 
Very stringent statistical thresholds are generally used to declare common variant susceptibility 
alleles at so-called genome-wide significance (P < 5×10-8). However, when there is limited statistical 
power, hundreds or thousands of single nucleotide polymorphisms (SNPs) with small effect sizes will not 
reach genome-wide significance (9). A key challenge in genetic epidemiology is to identify these risk 
SNPs with small effects. One approach is ever-larger studies allied to better coverage of common 
variation across the genome to increase statistical power.  However, even a case-control study with 
100,000 samples has just 23 per cent power to detect at genome-wide significance an allele of frequency 5 
per cent that confers a per-allele relative risk of 1.1. 
GWAS pathway analysis has emerged as a complement to imputation, single-variant testing and 
meta-analysis for the discovery of true genetic associations in the pool of SNPs that are below genome-
wide significance (10).  Pathway studies are guided by the hypothesis that true risk associations are more 
likely to cluster in genes that share a common biological function potentially dysregulated in disease 
pathogenesis. However, incomplete annotation and canonical representation of pathways in the literature 
are major limiting factors (11). 
One approach to overcome this limitation is by analyzing GWAS signals within the reduced 
search space of dynamic networks constructed from pairwise interactions observed in large, independent, 
tissue-specific transcriptomic data sets (12). Further, GWAS of cancer and other diseases increasingly 
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suggest that at least some genome-wide significant risk loci act through nearby transcription factor (TF) 
genes (13–15). Target genes of these TFs in turn have been found to be enriched for SNPs that fail to 
reach genome-wide significance but are nominally associated with the disease (16,17). Therefore, we 
adopted a risk locus TF gene-centric approach to integrating serous EOC transcriptomic and GWAS data 
sets. Seven of the 12 known genome-wide significant serous EOC risk loci harbor at least one TF gene in 
the 2 Mb interval centered on the top SNP at the locus. This includes nine members of the HOXD cluster 
and 10 members of the HOXB cluster at the 2q31 and 17q21.32 loci, respectively. The target genes of 
most homeobox (HOX) TFs remain largely unknown due to their promiscuous DNA binding properties in 
vitro (18). Since genes highly co-expressed with TF genes are more likely to represent their targets (19), 
and co-expression has been linked to shared function (20), we used the genes highly co-expressed with 
each TF in The Cancer Genome Atlas (TCGA) high-grade serous EOC microarray data set to build hub-
and-spoke type TF-target gene networks (21). We then systematically interrogated these networks for 
overrepresentation of genes containing SNPs ranked high for their association with serous EOC risk in a 
GWAS meta-analysis. Our aims were to prioritize hub TF genes whose networks demonstrated such 
overrepresentation as candidates for post-GWAS functional characterization and to use these networks to 
identify novel pathways and potential sub-genome-wide significant risk loci involved in serous EOC 
development. Most GWAS SNPs lie outside protein-coding regions of the genome and may affect cancer 
susceptibility by regulating a gene or genes up to a megabase away making such integrative genomic 
approaches to prioritizing genes in these 1 Mb regions imperative (22,23). 
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Materials and Methods 
 
Ranking genes based on GWAS results for serous EOC risk 
 
This study used P-values for association with serous EOC risk from a published meta-analysis of 
a North American and UK GWAS for 2,508,744 SNPs that were either genotyped or imputed in a total of 
2,196 serous EOC cases and 4,396 controls (1). The meta-analysis was restricted to subjects of European 
descent and the HapMap II (release 22) CEU panel served as reference for imputation. The North 
American and UK GWAS together with the replication data set described below are summarized in 
Supplementary Table S1. All participants provided written informed consent and each contributing study 
was approved by the appropriate local institutional ethical review board. A complete list of genes 
annotated with start and end positions of each gene was downloaded via the Bioconductor package 
TxDb.Hsapiens.UCSC.hg19.knownGene (v2.8.0). After removing genes with ambiguous location, all 
SNPs were mapped to genes with boundaries defined by the start and end positions. The genes were 
ranked in descending order of the negative logarithm (base 10) of the minimum P-value among all SNPs 
in each gene after adjusting this P-value for the number of SNPs in the gene using a modification of the 
Sidak correction (24). This accounts for linkage disequilibrium (LD) between SNPs while reducing the 
effect of gene size on the minimum P-value (25). Pearson’s r between gene size and minimum P-value 
improved from -0.3 to +0.1. Adequacy of correction was further confirmed by quantile-quantile plots 
(Supplementary Figure S1). In all, 10,693 genes that were also represented in the TCGA gene expression 
data set (described below) were ranked based on the GWAS results for subsequent analysis. 
 
Constructing serous EOC-specific co-expression networks with TF genes at risk loci as hubs 
 
We selected genes with experimentally confirmed transcription factor activity as described in 
Vaquerizas et al. (26) that were less than 1 Mb from the most significant SNP at each of the 12 loci (1–7) 
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known to be associated with serous EOC risk at genome-wide significance (Table 1). The SNPs listed in 
Table 1 were obtained from the Collaborative Oncological Gene-environment Study Primer (27). 
Nineteen of the 29 TF genes selected belonged to either the HOXB or the HOXD cluster. We relied on co-
expression in serous EOC tissue to define possible context-specific target genes of the TFs. 
Genes co-expressed with each selected TF gene were identified in the “unified expression” data 
set downloaded from TCGA (28). The data set contains expression measurements from three different 
microarray platforms unified into a single estimate for 11,864 genes in 489 high-grade serous ovarian 
adenocarcinoma samples (21). Four of the 29 TF genes were not represented in this data set and were 
therefore excluded. Co-expression was measured by mutual information (MI), a form of correlation, 
estimated using the adaptive partitioning method implemented in the Algorithm for the Reconstruction of 
Accurate Cellular Networks (ARACNE) (29). A threshold of P < 0.01 after Bonferroni correction for 
11,864 pairwise tests was set in ARACNE to retain only the genes most strongly co-expressed with each 
TF gene. 
 
Gene set enrichment analysis (GSEA) 
 
Each TF gene and the genes co-expressed with it were treated as a single hub-and-spoke network. 
GSEA (30) was used to determine overrepresentation of genes from the serous EOC-associated end of the 
ranked list generated on the basis of the GWAS meta-analysis, in each network. Before evaluating each 
network by GSEA, its parent hub TF gene was excluded from the network. Ten thousand permutations 
were performed with the number increased to 50,000 for networks with P = 0 at 10,000. Genes in the 
ranked list that were not among the 11,864 genes in the TCGA data set were excluded before GSEA as 
their co-expression with the TFs could not be evaluated. GSEA is optimized for gene sets/networks 
containing 15 to 500 genes (30). Applying this cut-off led to the exclusion of 11 of the 25 networks from 
the primary GSEA. We also conducted a secondary GSEA run allowing for networks with more than 10 
genes. This enabled evaluation of 24 out of the 25 co-expression networks. Only the network centered on 
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HOXD9 was excluded in the second GSEA run since it contained just six genes. Networks with GSEA P 
< 0.05 and FDR < 0.05 were considered significant. We also reported fold enrichment as the ratio of the 
number of genes from the top 5% of the ranked list that were observed in each network to the number 
expected. Cytoscape (v2.8.3) was used for network visualization (31). 
 
Replication analyses 
 
First, we examined the effect of LD between SNPs in closely spaced genes. The frequent co-
expression of genes co-localized on the genome coupled with LD between SNPs in such genes has the 
potential to inflate the GSEA signal (25). We subjected all SNPs in genes that were in the ranked list 
input to GSEA to LD-based clumping using PLINK (v1.07) (32) and CEU LD information from HapMap 
II (release 22). Starting from the most significant SNP, all SNPs with r2 > 0.7 within 250 kb of it were 
removed and the step repeated for the next best available SNP. Using the LD-thinned SNP list, SNP-to-
gene mapping, gene ranking and GSEA were repeated as described above. 
 Second, to replicate significant findings from our primary analysis, we used an independent data 
set from the Collaborative Oncological Gene-environment Study (COGS). The COGS data set included 
7,035 serous EOC cases and 21,693 controls of European descent after exclusion of overlap with the 
samples used in the primary analysis (Supplementary Table S1). These were genotyped using the iCOGS 
custom array (1) and imputed into the 1000 Genomes March 2012 EUR reference panel (Kuchenbaecker 
et al., under review). The imputed data set was filtered to retain 7,768,381 SNPs with minor allele 
frequency > 0.03 for consistency with the GWAS meta-analysis. SNP-to-gene mapping (without LD-
based clumping), gene ranking and GSEA were repeated as described above. 
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Analysis of combined network 
 
 The “leading-edge” subsets of genes from all co-expression networks that were significant in the 
primary analysis were combined into a single network. The leading-edge subset is the core of a gene set 
or network that drives its enrichment signal. It is defined as those members of the network that are ranked 
higher than the position in the ranked gene list where the network enrichment score is maximum (30). 
Subsequent analyses were conducted on genes in the combined network. 
 First, we input the genes to the Disease Association Protein-Protein Link Evaluator (DAPPLE, 
v1.0) (33). DAPPLE uses a database of 169,810 well-established pairwise interactions between 12,793 
proteins to connect input proteins (genes) directly or indirectly via a single protein not in the input. 
Biologically meaningful networks are more connected than random ones and DAPPLE tests the 
significance of indirect connectivity in the resultant network using permutation.  
 Second, we measured co-expression between each TF gene that was the hub of a significant 
network in the primary analysis and 17,255 other genes with expression levels profiled in the 245-sample 
Australian Ovarian Cancer Study (AOCS) serous EOC microarray data set (GSE9899) (34,35) using MI 
calculated by ARACNE. All 17,255 genes were ranked based on the strength of their co-expression with 
each hub TF. For each hub TF, we then counted the number of genes co-expressed with it in the 
combined network that were also observed among the top (strongest) 1% and top 10% of co-expression 
interactions for the TF in the AOCS data set as arbitrary estimates of tissue-specific replication of these 
co-expression-derived interactions. 
 Third, we used PSCAN (v1.2.2) (36) to test overrepresentation of known TF binding motifs from 
TRANSFAC (Human) (37) up to 1 kb upstream of transcription start sites of genes in the combined 
network. HOXB and HOXD motifs were absent in PSCAN but some homeodomain motifs were 
represented. 
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Results 
 
The network-based analytical strategy we used to integrate serous EOC GWAS and gene 
expression data sets is outlined in Figure 1. A total of 29 TF genes were located within 1 Mb of the top 
risk-associated SNP at seven of the 12 known genome-wide significant serous EOC risk loci (Table 1). Of 
these, four TFs were not represented in the TCGA data set used in this study and could not be evaluated 
further (Table 1). Computing pairwise mutual information between the somatic expression levels of each 
remaining TF gene (fixed as a hub) and the 11,863 other genes in the TCGA data set using an adaptive 
partitioning procedure with a Bonferroni-adjusted threshold of P < 0.01 to retain only the most strongly 
co-expressed genes yielded 25 hub-and-spoke type networks ranging in size from 6 to 1,953 genes. 
Fourteen TF genes from five risk loci were hubs of co-expression networks that included between 17 and 
368 genes placing them in the gene set size range (15 to 500 genes) optimal for GSEA (Tables 1 and 2). A 
total of 689,882 of the approximately 2.5 million SNPs from the serous EOC GWAS meta-analysis were 
located within the boundaries of 10,693 of the 11,864 genes represented in the TCGA data. These genes 
were ranked in descending order using the negative logarithm (base 10) of the modified Sidak-corrected 
minimum P-value among all SNPs in each gene. 
Six of the 14 networks tested by GSEA (with hubs HOXB2, HOXB7, HOXB6, and HOXB5 at 
17q21.32, and hubs HOXD3 and HOXD1 at 2q31) were significantly enriched for genes that ranked high 
for their association with serous EOC risk (GSEA P < 0.05 and FDR < 0.05; Table 2). The significant 
networks demonstrated between 1.5- and 8-fold enrichment for genes from the top 5% of the ranked list 
as compared to expectation (Table 2). Supplementary Table S2 lists the genes in each significant network. 
The six networks identified by the primary analysis remained significant in replication analysis 
using the linkage disequilibrium-thinned SNP list indicating that the primary GSEA signals were not 
being driven by strongly correlated SNPs in closely spaced genes (Supplementary Table S3). All six 
networks were also significantly associated (P = 0.03 to 4×10-4) with serous EOC risk in replication 
analysis using the independent COGS data set (Supplementary Table S4). Next, we observed that 33 
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genes were shared by more than one of the six networks. Further, 18 genes across the six networks were 
located less than 1 Mb from the most significantly-associated SNPs at the 2q31 and 17q21.32 risk loci. To 
eliminate potential inflation of the GSEA signal due to genes co-expressed locally with the hub TF genes 
anchoring the significant networks, we pooled the 249 genes in the six original networks and removed the 
18 genes at 2q31 and 17q21.32. We also counted the overlapping genes only once in the pooled network. 
The result was a set of 174 genes of which 170 were covered by SNPs in the COGS data set. This filtered 
set was also significantly associated with serous EOC risk in GSEA using the ranked gene list derived 
from the COGS data (P = 0.007). A secondary GSEA run with less stringent parameters that allowed 
inclusion of the 24 co-expression networks with more than 10 genes (including the 10 previously 
excluded networks containing > 500 genes) did not identify any additional significant networks at the P < 
0.05 and FDR < 0.05 threshold (Supplementary Table S5). Supplementary Table S6 shows differences in 
the number of genes from the TCGA data set covered by intragenic SNPs in the ranked lists generated 
from the GWAS meta-analysis, LD-thinned, and COGS data sets. 
Given that all networks significant in the primary analysis were centered on hub TFs from the 
HOX gene family and the observation that some of their targets were shared, we merged the leading edge 
subsets (i.e., the genes underlying the GSEA signal) from each of the six networks. This yielded a 
combined network of 50 non-redundant genes most strongly associated with serous EOC risk and 81 
interactions between them (Figure 2). The 50 genes were submitted as input to the web-based tool, 
DAPPLE, to determine if they demonstrate significant connectivity at the protein-protein interaction (PPI) 
level, a frequent characteristic of disease associated networks (38). DAPPLE connected the proteins 
encoded by the genes using a database of high-confidence PPIs, allowing for connections between input 
genes/proteins that were either direct or indirect via a single intermediate protein not in the input group. 
Two PPI networks were formed (Supplementary Figure S2), with the larger network involving 29 of the 
50 input genes/proteins. Compared to 10,000 permuted networks with similar underlying topology, the 
input proteins were more likely to be connected to each other indirectly (through a single intermediate 
protein) than expected by chance alone (P = 0.01). Next, we evaluated whether the genes co-expressed 
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with the hub TF genes in the combined network were more likely to be among the genes most strongly 
co-expressed with the same TFs in an independent microarray data set from the Australian Ovarian 
Cancer Study. All interactions in the combined network between a hub TF gene and another HOX cluster 
gene and 25/44 (57%) hub TF and non-HOX cluster gene interactions were among the top 10% of 
interactions for the corresponding hub TF in the AOCS data set (for HOX non-HOX interactions, 
binomial test P = 2×10-14). In fact, 32/37 (86%) HOX-HOX and 13/44 (30%) HOX-non-HOX interactions 
were seen at a more stringent top 1% level (for HOX non-HOX interactions, binomial test P = 4×10-16). 
HOX-HOX interactions were analyzed separately since HOX cluster members are already known to 
interact with each other (39). Finally, we assessed enrichment of known TF binding motifs up to 1 kb 
upstream of the 40 non-HOX cluster genes in the combined network using the online tool PSCAN to look 
for possible overrepresentation of the few homeodomain motifs that are well established. The binding 
motif for the cooperative homeodomain TFs, HOX-A9-MEIS1, was the second most overrepresented 
among the 40 non-HOX cluster genes in the combined network (P = 0.008), second only to the motif for 
SPZ1 (P = 0.006). Thus, the AOCS data set and the PSCAN tool further supported the TF-target gene 
interactions observed in the combined network. 
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Discussion 
 
 In this study, we used network analysis to integrate TCGA gene expression data with GWAS 
meta-analysis summary findings to identify six networks significantly associated with serous EOC risk 
and replicated our results using the independent COGS data set. Network construction was guided by the 
premise that TF genes near genome-wide significant serous EOC risk SNPs may be the functional targets 
of these SNPs. The TFs may regulate pathways of target genes, represented by genes strongly co-
expressed with each TF gene that are, in turn, enriched for SNPs nominally associated with serous EOC 
susceptibility. The product of the multi-step analysis presented here is a combined network of 50 genes 
and 81 interactions (Figure 2). A significant proportion of these interactions were further supported by co-
expression analysis in the independent AOCS microarray data set. 
Hub TF genes of the six significant networks and the genes in their combined network suggest 
that specific members of the HOXD and HOXB clusters potentially mediate the effects of the 2q31 and 
17q21.32 serous EOC risk loci, respectively. While this analysis was ongoing, a parallel comprehensive 
functional follow-up of the 2q31 locus revealed that SNPs at this locus impact serous EOC development 
through HOXD9 (Lawrenson et al., submitted). HOXD9 could not be evaluated as a hub TF using GSEA 
since its network contained just six genes (including HOXD1 and HOXD3) at the stringent cut-off we 
used for identifying only the most strongly co-expressed genes. However, it is worth noting that HOXD9 
is a leading edge or core member of two of the significant networks identified (centered on HOXD1 and 
HOXD3) and therefore appears in the combined network uncovered by this analysis (Figure 2). Thus, 
HOXD9 may have a putative master regulatory role upstream of HOXD1 and HOXD3 in serous EOC 
development. At 17q21.32, HOXB5, HOXB6 and HOXB7 have collectively been implicated in early 
carcinogenic reprogramming of transcription in epithelial cells (40). HOXB7 is also known to be involved 
in DNA repair catalyzed by poly(ADP-ribose) polymerase (41). HOXB7 expression is elevated in ovarian 
cancer and overexpression is associated with marked proliferation of immortalized normal ovarian surface 
epithelial cells by upregulation of basic fibroblast growth factor (42). Hypermethylation of HOXB5, a 
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possible tumor suppressor, is also a frequent somatic change reported in ovarian cancer and 
corresponding in vitro models (43). Overall, the identification of a novel HOX-centric pathway is 
consistent with the emerging role of developmental genes in ovarian carcinogenesis (44). Other members 
of the HOX gene family have previously been shown to guide both reproductive tract patterning during 
early development and epithelial ovarian cancer cellular morphology (45). 
A striking feature of the combined network is that it connects genes at five of the 12 genome-
wide significant serous EOC risk loci. This is particularly compelling because only TF genes from two of 
these loci (2q31 and 17q21.32) were used as seed hubs for the six significant networks that underlie the 
combined network. The other three were picked up by the combination of co-expression and enrichment 
analysis, that is, without any a priori input. A small number of genes contribute to the combined network 
from the three non-hub loci in this group of five: BNC2 (HOXD1 network member) at 9p22; HNF1B 
(HOXB6 and HOXB7 networks) and LHX1 (HOXD1 network) at 17q12; and ABHD8 (HOXB7 network) 
at 19p13. Serous EOC risk SNPs at 17q12 have previously been associated with significantly higher 
HNF1B methylation (46). Likewise, the SNPs at the 9p22 risk locus are likely to represent multiple 
transcriptional regulatory elements acting on BNC2 based on an integrated functional analysis (Buckley et 
al., in preparation). Finally, functional work on 19p13 indicates that ABHD8 is the most likely target of 
serous EOC and breast cancer risk SNPs at this locus (Lawrenson et al., in preparation) (4,47). Taken 
together, these findings for ABHD8, HNF1B and BNC2 underscore the power of integrating GWAS with 
tissue-specific gene expression data in a network paradigm to prioritize the genes likely to be regulated by 
genome-wide significant risk variants for downstream functional characterization (23). 
The addition of orthogonal biological priors to statistical evidence from GWAS may also unravel 
interesting targets at loci that are nominally significant but fail to reach genome-wide significance. For 
example, the oncogene WT1 that appears in the combined network is a highly specific serous ovarian 
lineage marker (48). The top SNP in this gene has P = 0.012 in the GWAS meta-analysis that strengthens 
to P = 0.0078 in the COGS data set. However, while it is intriguing to identify such possible functional 
targets associated with serous EOC susceptibility, it will require extensive experimental validation to 
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confirm their role in disease predisposition. Profiling of the relevant HOXB and HOXD transcription 
factor binding in fallopian tube and ovarian surface epithelial cells and in ovarian cancer cells may 
identifying binding sites containing serous EOC risk SNPs analogous to what has been done to establish 
the role of other TFs in breast cancer susceptibility (49,50). The emergence of genome editing 
technologies such as the CRISPR-Cas9 system may further enable modification of risk SNPs in these 
HOX binding sites to modulate and confirm the role of the HOX target genes in cellular models that 
reflect early stages of ovarian cancer (51). 
The observation that 29 of the 50 genes in the combined network were also part of a protein-
protein interaction network with significant indirect connectivity suggests that this gene network is 
biologically coherent. The failure to capture the remaining 21 co-expressed genes in the PPI network also 
hints that some interactions are perhaps tissue-specific and/or specific to the transcriptome since 
DAPPLE, the tool used for the PPI network analysis, relies on protein interactions found in different 
tissues (33). 
 There are limitations inherent in this study. GSEA is optimized to detect enrichment in gene sets 
or networks containing between 15 and 500 genes. Although we applied it to the 10 networks containing 
more than 500 genes in a secondary analysis, our failure to detect any additional significant networks 
among the very large networks does not rule out the presence of genuine enrichment in these networks. 
Co-expression is likely not the perfect proxy for defining TF targets and the risk locus-TF gene and TF-
target gene interactions suggested by this analysis warrant follow-up. 
In conclusion, by identifying a HOX-centric gene co-expression network associated with serous 
EOC risk, this report highlights the potential of network analysis to combine GWAS with other molecular 
data to offer insights into the mechanisms linking population studies with cancer biology. 
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Tables 
 
Table 1. Summary of 12 genome-wide significant serous EOC risk loci 
       
Locus SNP Chr Position OR 95% CI TF genes < 1 Mb away from SNP 
2q31 rs711830 2 177,037,311 1.12 1.08-1.15 HOXD1, HOXD3, HOXD4a,  
      HOXD8a, HOXD9b, HOXD10, 
      HOXD11b, HOXD12b, HOXD13b 
3q25 c3_pos157917010 3 157,917,010 1.44 1.35-1.54 SHOX2 
4q32c rs4691139 4 165,908,721 1.2 1.17-1.38  
5p15 rs10069690 5 1,279,790 1.09 1.05-1.13 IRX4b 
8q21 rs11782652 8 82,653,644 1.19 1.12-1.26  
8q24 rs7814937 8 129,541,475 1.18 1.13-1.24 MYC 
9p22 rs3814113 9 16,915,021 1.21 1.17-1.25  
10p12 rs7084454 10 21,821,274 1.1 1.06-1.14  
17q12 rs7405776 17 36,093,022 1.12 1.08-1.17 HNF1Bb 
17q21.31 rs2077606 17 43,529,293 1.15 1.12-1.19  
17q21.32 rs7218345 17 46,502,917 1.12 1.08-1.16 HOXB1b, HOXB2, HOXB3, 
      HOXB4a, HOXB5, HOXB6, HOXB7 
      HOXB8b, HOXB9b, HOXB13b, 
      SP2, SP6a, TBX21, NFE2L1 
19p13 rs8170 19 17,389,704 1.14 1.09-1.17 KLF2b, NR2F6 
aTranscription factor gene was not represented in the TCGA data set.  
bTranscription factor gene excluded because it was the hub of a co-expression network with < 15 or > 500 genes. 
cAssociated with serous EOC risk in BRCA1 mutation carriers only (7). 
Abbreviations: Chr: chromosome; OR: odds ratio; CI: confidence intervals. 
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Table 2. GSEA results for 14 serous EOC risk locus TF-centric gene co-expression networksa 
       
Serous EOC Network hub Co-expression Normalized Nominal FDR Top 5% 
risk locus TF gene network size enrichment P-value q-value fold enrichment 
17q21.32 HOXB2 17 1.64 2.0E-05b 4.0E-05b 8.00 
17q21.32 HOXB7 31 1.62 0b 5.0E-05b 4.50 
17q21.32 HOXB6 33 1.43 5.0E-04 3.0E-03 4.50 
2q31 HOXD3 52 1.39 5.0E-04 4.9E-03 3.67 
17q21.32 HOXB5 30 1.37 4.0E-03 5.1E-03 3.00 
2q31 HOXD1 69 1.25 8.1E-03 0.04 1.50 
17q21.32 SP2 134 1.18 7.7E-03 0.09 1.57 
17q21.32 HOXB3 103 1.18 0.02 0.08 2.17 
17q21.32 TBX21 46 1.10 0.19 0.22 1.33 
17q21.32 NFE2L1 315 1.06 0.12 0.35 1.06 
19p13 NR2F6 312 1.04 0.23 0.43 1.50 
8q24 MYC 130 1.02 0.37 0.45 0.71 
3q25 SHOX2 368 1.00 0.53 0.56 0.95 
2q31 HOXD10 85 1.00 0.52 0.52 0.80 
aHub-and-spoke networks containing 15 to 500 genes constructed from serous EOC TCGA data. 
bFor 50,000 permutations, since nominal P-value = 0 at the default number of 10,000 permutations. 
 
 
 
     
 
 
 
Figure Legends 
 
Figure 1. Outline of steps involved in the integrated analysis of GWAS and tissue-specific expression 
data sets to identify, replicate and computationally follow-up gene networks associated with serous EOC 
susceptibility. 
 
Figure 2. Cytoscape visualization of the combined network. Hub TF genes of the six significant networks 
underlying the combined network are outlined in green. Candidate genes at genome-wide significant risk 
loci other than the input hub loci (2q31 and 17q21.32) are outlined in blue. Nodes are colored according 
to the P-value of the most significant intragenic SNP in the GWAS meta-analysis (uncorrected for the 
number of intragenic SNPs). Diamond shaped genes have P < 0.05 after applying the modified Sidak 
correction. 
